New report prompts debate about the representation of women in pharmacy leadership
The relative absence of women in leadership roles in pharmacy has again been raised as an issue after a new report highlighted the continuing gender imbalance in leadership roles in Australian businesses.
The latest Gender diversity progress report from the Australian Institute of Company Directors reveals many companies are not meeting their target of having at least 30 per cent female membership of their boards.
The report found female board membership was 21.5% across the the S&P/ASX 200 companies.
Medibank Private topped the list with five female directors, accounting for 62.5% of its board.
Results for health-related companies were not so good, although pharma company CSL did pass the 30% barrier.
- CSL 3 female directors (33.3% of board)
- Australian Pharmaceutical Industries 2 (28.6%)
- Blackmores 2 (28.6%)
- Ramsay Health Care 2 (20%)
- Sigma Pharmaceuticals 1 (16.7%)
- Primary Health Care 1 (12.5%)
- Mayne Pharma Group 0
The report has prompted social media comment from pharmacists asking if their industry bodies could meet the 30% board mark.
— Debbie Rigby (@DRugby56) March 28, 2016
Wondered if it was weird for men to look around table & see only other men..but I guess for many it seems normal! https://t.co/9bzTniD9vG
— Alison Roberts (@alison_roberts1) March 28, 2016
There had been much discussion about the number of women included in panel discussions at the recent APP2016 conference.